Company Overview and News

31
Week In Review: Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuation

2018-07-15 seekingalpha
Tasly Biopharma (SHA:600535) of Shanghai raised $84.5 million in new capital from a group of investors that included Ally Bridge. The funding is a pre-IPO round as Tasly is planning to list on the Hong Kong Exchange. The investors received a 4.5% stake in Tasly Biopharma, implying a $1.9 billion pre-IPO valuation. Tasly Biopharma is the novel drug development arm of Tasly Pharma. As a separate part of the transaction, Transgene (OTCPK:TRGNF) (P:TNG) transferred its half of a China drug JV to Tasly in exchange for $48 million of stock, raising the deal's value to $132.
MKGAF IBIO MKGAY TNG NVS

0
Church & Dwight Vs. Procter & Gamble: The Discrepancy In Valuations Continues To Widen

2018-07-13 seekingalpha
Both companies experienced pricing weakness during their most recent quarters, but CHD was saved by solid growth in volumes.
MKGAF MKGAY

0
Virtual Reality: A Potential New Tool in Healthcare and Therapy R&D

2018-07-09 biospace
Andrew Huberman, researcher in the Stanford University Department of Neurobiology, is taking an unusual approach to investigating possible treatments for glaucoma and anxiety disorders—virtual reality. Although uncommon, the use of virtual reality and various high-level imaging techniques are being used in several areas of drug development and treatment.
MKGAF MKGAY

21
Forty Seven IPO: Google Has A Stake, But Other Competitors Trade At Lower Valuations

2018-07-06 seekingalpha
Entities affiliated with Google own 5.2% stake in the company. Clients of Wellington Management Company have 6.8% stake as well.
ORPHF ABT MKGAF AMGN CELGZ GILD SURF GOOG TRIL ABT RHHBF ARTH RHHVF MKGAY MRK CELG RHHBY FTSV PDLI

0
Juniper Inks Deal to be Acquired by Catalent, Shares Up

2018-07-04 zacks
Shares of healthcare company Juniper Pharmaceuticals, Inc. (JNP - Free Report) jumped by about 31.6% after the company entered into a definitive agreement with Catalent, Inc. (CTLT - Free Report) , as per which Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
ANIP MKGAF BLT MKGAY BHP JNP BHPBF CTLT BBL BHP BHPLF

0
Catalent Flexes M&A Muscle, Acquires Juniper Pharmaceuticals

2018-07-03 biospace
Shares of Juniper Pharmaceuticals have soared more than 31 percent in premarket trading after the company announced it will be acquired by drug delivery company Catalent, Inc. in a deal with a total equity value of approximately $139.6 million.
MKGAF MKGAY JNP

0
Catalent to Acquire Juniper, Adding Early Drug Development Capabilities

2018-07-03 genengnews
Catalent has agreed to acquire Juniper Pharmaceuticals for $133 million, in a deal that would add a U.K. center of excellence for early drug development to similar centers that the buyer established on the West Coast and plans to create on the East Coast. [Juniper Pharma Services]
MKGAF MKGAY JNP

1
Catalent to buy Juniper Pharmaceuticals for $11.50 per share

2018-07-03 reuters
(Reuters) - U.S. drug contract manufacturer Catalent Inc (CTLT.N) said on Tuesday it will buy Juniper Pharmaceuticals Inc (JNP.O) for $11.50 per share in cash.
MKGAF MKGAY JNP CTLT

0
Deborah Dunsire Takes Over as CEO of Denmark’s H. Lundbeck

2018-07-02 biospace
Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S. She takes over as head of Lundbeck following the departure of Kåre Schultz, who left the company to helm Teva Pharmaceuticals.
MKGAF MKGAY

78
RPT-FOCUS-AI ambulances and robot doctors: China seeks digital salve to ease hospital strain

2018-06-28 reuters
HANGZHOU, China/SHANGHAI, June 28 (Reuters) - In the eastern Chinese city of Hangzhou, an ambulance speeds through traffic on a wave of green lights, helped along by an artificial intelligence (AI) system and big data.
MKGAF BABA MKGAY

19
Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®

2018-06-28 globenewswire
BOSTON, June 28, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with recurrent glioblastoma (rGBM).
ZIOP MKGAF XON MKGAY

78
AI ambulances and robot doctors: China seeks digital salve to ease hospital strain

2018-06-28 channelnewsasia
In the eastern Chinese city of Hangzhou, an ambulance speeds through traffic on a wave of green lights, helped along by an artificial intelligence (AI) system and big data.
MKGAF BABA MKGAY

78
FOCUS-AI ambulances and robot doctors: China seeks digital salve to ease hospital strain

2018-06-28 reuters
HANGZHOU, China/SHANGHAI (Reuters) - In the eastern Chinese city of Hangzhou, an ambulance speeds through traffic on a wave of green lights, helped along by an artificial intelligence (AI) system and big data.
MKGAF BABA MKGAY

18
Top 5 Women Executives in the Biopharma Industry by Compensation

2018-06-26 biospace
In 2017, the Massachusetts Biotechnology Council (MassBIO) and Liftstream, an executive recruiting company, issued a report, “Opening the Path to a Diverse Future.” The report cited that the percentage of men and women entering biopharma were almost equal, with 49.6 percent women and 50.4 percent men, but women only made up 24 percent of C-suite executives, and only 14.4 percent of company boards.
MKGAF GD REGN 506285 MKGAY GM.WS.A GM.WS.B GM.WS.C UTHR GM GM.WSB BYRQY BAYERCROP

7
The Dementia Discovery Fund Raises $350 Million from Investors AARP, NFL and Others

2018-06-26 biospace
The Dementia Discovery Fund (DDF), a London-based venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
MKGAF MKGAY DGX WPCT UNH

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

CUSIP: 589339100